Radicle Calm 1: A Study of Health and Wellness Products on Feelings of Anxiety, Stress and Other Health Outcomes

Sponsor
Radicle Science (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05589948
Collaborator
(none)
1,231
1
5
10
122.8

Study Details

Study Description

Brief Summary

A randomized, blinded, placebo-controlled, direct-to-consumer study assessing the impact of health and wellness products on feelings of anxiety, stress and other health outcomes

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Radicle Calm Study Placebo Control 1
  • Dietary Supplement: Radicle Calm Study Placebo Control 2
  • Dietary Supplement: Radicle Calm Study Active Product 1.1
  • Dietary Supplement: Radicle Calm Study Active Product 2.1
  • Dietary Supplement: Radicle Calm Study Active Product 2.2
N/A

Detailed Description

This is a randomized, blinded, placebo-controlled study conducted with up to 300 adult participants per study arm, age 21 and older and residing in the United States.

Eligible participants will (1) endorse a desire for less feelings of anxiety and/or stress, (2) indicate an interest in taking a health and wellness product to potentially improve their anxiety and/or stress, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants with known liver or kidney disease, heavy drinkers, and those who are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded.

Self-reported data will be collected electronically from eligible participants over 5 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1231 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants will be stratified based on gender at birth then randomized to one of the study armsParticipants will be stratified based on gender at birth then randomized to one of the study arms
Masking:
Single (Participant)
Masking Description:
Participants will be blinded to the product they receive.
Primary Purpose:
Other
Official Title:
Radicleâ„¢ Calm 1: A Randomized, Blinded, Placebo-Controlled Direct-to-Consumer Study of Health and Wellness Products on Feelings of Anxiety, Stress and Other Health Outcomes
Actual Study Start Date :
Oct 10, 2022
Anticipated Primary Completion Date :
Jan 14, 2023
Anticipated Study Completion Date :
Aug 11, 2023

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo Control 1

Calm Product Form 1 - control

Dietary Supplement: Radicle Calm Study Placebo Control 1
Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.

Placebo Comparator: Placebo Control 2

Calm Product Form 2 - control

Dietary Supplement: Radicle Calm Study Placebo Control 2
Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.

Experimental: Active Product 1.1

Calm Product Form 1 - active product 1

Dietary Supplement: Radicle Calm Study Active Product 1.1
Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.

Experimental: Active Product 2.1

Calm Product Form 2 - active product 1

Dietary Supplement: Radicle Calm Study Active Product 2.1
Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.

Experimental: Active Product 2.2

Calm Product Form 2 - active product 2

Dietary Supplement: Radicle Calm Study Active Product 2.2
Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.

Outcome Measures

Primary Outcome Measures

  1. Change in feelings of anxiety [4 weeks]

    Mean difference in feelings of anxiety score as assessed by Patient Reported Outcome Measurement System (PROMIS) Anxiety 8A (scale 8-40; where lower scores correspond to less feelings of anxiety)

Secondary Outcome Measures

  1. Minimal clinically important difference (MCID) in anxiety [4 weeks]

    Likelihood of experiencing a MCID in anxiety score as assessed by PROMIS Anxiety 8A

  2. Change in stress [4 weeks]

    Mean difference in stress score as assessed by PROMIS Stress 8A (scale 8-40; where lower scores correspond to less stress)

  3. Minimal clinically important difference (MCID) in stress [4 weeks]

    Likelihood of experiencing a MCID in stress score as assessed by PROMIS Stress 8A

  4. Change in sleep disturbance [4 weeks]

    Mean difference in sleep disturbance score as assessed by PROMIS Sleep 4A (scale 4-20; where lower scores correspond to better sleep quality/less sleep disturbance)

  5. Change in cognitive function [4 weeks]

    Mean difference in cognitive function score as assessed by PROMIS Cognition Function 4A (scale 4-20; where lower scores correspond to poorer cognitive function)

Other Outcome Measures

  1. Change in mood (emotional distress) [4 weeks]

    Mean difference in mood score as assessed by PROMIS Emotional Distress-Depression 4A (scale 4-20; where lower scores correspond to lower levels of emotional distress)

  2. Change in libido [4 weeks]

    Mean difference in libido score as assessed by PROMIS Sexual Interest 2.0 (scale 4-20; where lower scores correspond to less interest in sexual activity)

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 105 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities

  • Resides in the United States

  • Endorses feelings of anxiety or stress as a primary issue (desire to reduce anxiety or less stress)

  • Selects feelings of anxiety/stress, looking to improve their feelings of anxiety/stress, and/or reduce reliance on medications as a reason for their interest in taking a health and wellness product

  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion Criteria:
  • Pregnant, trying to become pregnant, or breastfeeding

  • Unable to provide a valid physical shipping address

  • Reports a diagnosis of liver or kidney disease

  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)

  • Unable to read and understand English

  • Lack of reliable daily access to the internet

  • Reports taking anticoagulants, any medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, or MAOIs

  • Reports current or recent (within 3 months) use of chemotherapy, immunotherapy, or oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection

Contacts and Locations

Locations

Site City State Country Postal Code
1 Radicle Science, Inc Del Mar California United States 92014

Sponsors and Collaborators

  • Radicle Science

Investigators

  • Principal Investigator: Emily K. Pauli, PharmD, Radicle Science, Inc

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Radicle Science
ClinicalTrials.gov Identifier:
NCT05589948
Other Study ID Numbers:
  • RADX-22D04
First Posted:
Oct 21, 2022
Last Update Posted:
Jan 11, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 11, 2023